Mal de Debarquement Syndrome (MdDS) Treatment at Mount Sinai

Announcement

Clinical Trial Study: Developing Robust Treatment Options for Mal de Débarquement Syndrome

May 15, 2024

Human Balance Laboratory at the Neurology Department of Icahn School of Medicine at Mount Sinai

The purpose of this research study is to develop better treatment options for mal de débarquement Syndrome (MdDS). MdDS is an under-recognized balance disorder, which in most cases follows a long ride on a ship or plane and is characterized by sensations of rocking/swaying or gravitational pull. Patients with MdDS typically experience additional symptoms such as increased sensitivity to visual motion (visually induced dizziness, VID), physical motion (motion sickness, MS), and other physical, or sensation problems. Treatment options for MdDS are limited, but it was recently shown that a therapy developed in our laboratory combining vision and head motion yielded significant long-term improvement of symptoms in about 50% of patients. This research will build on this success by: 1) testing the usefulness of virtual reality (VR) technology as a treatment; 2) supplementing the original treatments with an additional treatment that focuses on VID or MS symptoms; and 3) testing treatments that address gravitational pull sensation.

You may qualify to take part in this research study if:

You are in age range 18-78.
You are not blind and do not have severe vestibular (visual), cerebellar (brain) or locomotion disorders (movement).
You report a sensation of non-spinning vertigo (rocking, swaying, bobbing, walking on a trampoline, gravitational pull) or pulling, which are present while lying down, sitting, or standing and temporarily stop during passive transportation such as a car ride.
You can stay within 1 hour from our laboratory in New York City during the five-day period of experimental treatment.
You do not take benzodiazepines on a daily basis. If you do, consult with your doctor whether the medication can be weaned off with supervision and/or have it replaced with an alternative medication.

Your participation in this research study is expected to last for 6 months after the treatment in the form of follow-up questionnaires. A total of 200 people are expected to take part in this research study.

If you are interested in participating in this study, please contact

Sergei Yakushin, PhD, (212) 241-9349, sergei.yakushin@mssm.edu
Jun Maruta, PhD, (212) 241-7068, jun.maruta@mountsinai.org

Funds for conducting this research are provided by the National Institute of Health/National Institute of Deaf and Other Communication Disorders (NIH/NIDCD).

For more information, please visit:

https://classic.clinicaltrials.gov/ct2/show/NCT05460520

The Treatment

Treatment of Mal de Debarquement Syndrome (MdDS) by habituation of Velocity Storage

Mal de Debarquement Syndrome (MdDS) is an under-recognized but nevertheless common balance disorder, which in most cases occurs after exposure to prolonged passive motion. MdDS is manifested by constant postural rocking/swaying or gravitational pull of the body, and accompanied by high sensitivity to light, noise, or crowds, or cognitive dysfunctions including short term memory impairment. In addition to motion-triggered (MT) cases of MdDS, similar symptoms can occur without a clear trigger, identified as spontaneous MdDS. We recently developed the first effective treatment method for MdDS based on readaptation of the vestibulo-ocular reflex (VOR). Over the past several years, more than 600 patients from around the world have been treated with this method. The hypothesis underlying this treatment is that MdDS is caused by maladaptation of a functional component of the VOR called velocity storage, whose readaptation can be stimulated by exposure to whole-field visual motion coupled with head tilts. Our current success rate immediately after treatment of MT MdDS is 75%. However, some patients report return of symptoms after flights or prolonged car rides following a treatment. Thus, for some patients, the effectiveness of the current MdDS treatment protocol appears to depend on a serious practical limitation of needing to permanently avoid transportation. Building on the previous hypothesis of velocity storage maladaptation, we currently hypothesize that reduction (habituation) of velocity storage can also resolve MdDS symptoms. Velocity storage can be significantly habituated by 4-5 days of treatment with a protocol previously designed in our laboratory to reduce susceptibility to motion sickness. Preliminary data support that velocity storage habituation reduces MdDS symptoms.

In this project, 30 motion triggered MdDS patients with no history of inner ear problems and no severe neurological decoders will be randomly assigned into two groups. Group 1 will be treated with the habituation protocol only, and Group 2 will be treated with the VOR readaptation protocol only. Patients will be followed up for up to 6 months.

Based on the preliminary data, we expect both groups to experience similar initial symptom improvement, but Group 1, undergoing the habituation protocol, to better retain the initial treatment impact. This project will broaden treatment options for MdDS and increase the current understanding of recurrent MdDS.

If you would like to participate in this study, please contact Dr. Sergei Yakushin, PhD by email at sergei.yakushin@mssm.edu.

Recently, our research has focused on motion sickness in MdDS. We are working to raise $10,000 for a small pilot study to determine whether the motion sickness protocol for MdDS patients can improve the motion sensitivity commonly seen in concussion patients. To make your donation, please contact Mr. Thom Harmon at thomas.harmon@mountsinai.org and specify that the donation is for Dr. Yakushin's concussion research.